Oncology
For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreFor years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
It took 10 years of treatments for Anisha's IBD to enter remission. But it came back in 2019 — and just as she was about to start treatment, the pandemic hit.
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
By Martin Roessner, Corporate VP, Biostatistics
By David Brown, Vice President, Epidemiology
By Sheng Feng, Ph.D. (冯胜), Corporate Vice President, RWE APAC
As the world raced to develop vaccines and therapeutics to combat the global coronavirus pandemic in 2020, the use of real-world evidence (RWE) accelerated because it offers an opportunity to support faster, more cost-effective drug and vaccine development. It also benefits clinical trial patients with rare and life-threatening diseases. For example, RWE-based external control arms could ensure patients receive an active treatment in a clinical trial, rather than be allocated to a placebo control regimen. The United States and China are at the forefront of exploring how RWE could support regulatory decisionmaking.
At Parexel, we’ve learned how companies can be more effective at collecting real-world data (RWD) and generating RWE. In this article, we share our most valuable lessons.
Related Insights
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Video
The science and practice of ethnobridging
May 17, 2023
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
How RWE can help Biotechs optimize the value of their asset
Apr 5, 2021